Advertisement

Topics

Clinical Trials About "Deutsche Telekom AG" RSS

06:05 EDT 21st July 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Deutsche Telekom AG" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Deutsche Telekom AG" on BioPortfolio

We have published hundreds of Deutsche Telekom AG news stories on BioPortfolio along with dozens of Deutsche Telekom AG Clinical Trials and PubMed Articles about Deutsche Telekom AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Deutsche Telekom AG Companies in our database. You can also find out about relevant Deutsche Telekom AG Drugs and Medications on this site too.

Showing "Deutsche Telekom" Clinical Trials, all 3

Relevant

A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)

The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the Deutsche Diabetes Gesellschaft (DDG) on October 13, 2008


Probably Relevant

Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders

To investigate and compare the efficacy, safety and tolerability of ziprasidone versus placebo in the treatment of conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS) of older children and adolescents in an outpatient setting. Conduct and other behavior disorders are some of the most common forms of psychopathology in children and adolescents. The main characteristic of these disorders is a repetitive an...

Effects of Empagliflozin Plus Linagliptin vs Metformin Plus Insulin Glargin on Renal and Vascular Changes in Type 2 Diabetes

Diabetes mellitus is a wide-spread disease accompanied by strongly increased morbidity and mortality due to micro- and macrovascular complications. However, in studies with patients suffering from diabetes mellitus type 2 (DM 2), early changes and impairments in large and small blood vessels as well as organ damage (e. g. to the kidneys) have been only insufficiently investigated (1). The newest substance class in oral antidiabetics, i. e. SGLT-2-inhibitors (such as empaglifloz...



More From BioPortfolio on "Deutsche Telekom AG"

Advertisement
Quick Search
Advertisement
Advertisement